364 related articles for article (PubMed ID: 18586919)
21. Philadelphia chromosome positive myelodysplastic syndrome and acute myelogenous leukemia.
Advani AS
Leuk Res; 2004 Jun; 28(6):545-6. PubMed ID: 15120928
[No Abstract] [Full Text] [Related]
22. Recent advances in biological and therapeutic aspects of myeloproliferative disorders.
Mancini M; Diverio D; Alimena G; Mandelli F
Curr Opin Hematol; 1994 Jul; 1(4):261-7. PubMed ID: 9371292
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
Sadiq SA; Rammal M; Sara G
Mult Scler; 2008 Mar; 14(2):272-3. PubMed ID: 17986509
[TBL] [Abstract][Full Text] [Related]
24. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
Dvorak P; Hruba M; Subrt I
Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
[No Abstract] [Full Text] [Related]
25. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
26. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
27. CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
Bolaños-Meade J; Sarkodee-Adoo C; Khanwani SL
Am J Hematol; 2002 Oct; 71(2):139. PubMed ID: 12353319
[No Abstract] [Full Text] [Related]
28. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
29. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
30. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
31. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea-induced fever in a patient with chronic myelogenous leukemia.
Tsurumi H; Goto H; Hara T; Moriwaki H
Int J Hematol; 2000 Oct; 72(3):386-7. PubMed ID: 11186000
[No Abstract] [Full Text] [Related]
33. A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13).
Pidala J; Pinilla-Ibarz J; Cualing HD
Cancer Genet Cytogenet; 2008 Apr; 182(1):46-9. PubMed ID: 18328951
[TBL] [Abstract][Full Text] [Related]
34. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
Chen JY; Wang MC; Hung WC
Leuk Res; 2009 Nov; 33(11):1520-4. PubMed ID: 19329185
[TBL] [Abstract][Full Text] [Related]
36. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
[No Abstract] [Full Text] [Related]
37. Chronic myelogenous leukemia, BCR-ABL1+.
Vardiman JW
Am J Clin Pathol; 2009 Aug; 132(2):250-60. PubMed ID: 19605820
[TBL] [Abstract][Full Text] [Related]
38. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous presence of major secondary chromosomal abnormalities in blast crisis of chronic myeloid leukemia.
Lu CM; Wang E; Lawrence HJ
Cancer Genet Cytogenet; 2007 Jan; 172(2):174-5. PubMed ID: 17213030
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
